Monopar Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$0
$0
EBITDA
-1,788
-1,723
-1,911
EBIT
-3,577
-3,446
-3,823
Net Income
-1,715
-1,641
-1,813
Net Change In Cash
0
0
0
Free Cash Flow
-1,676
-1,655
-1,545
Cash
6,119
7,807
7,266
Basic Shares
3,502
15,979
14,904

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$0
$0
$0
$122
Gross Profit
122
EBITDA
429
-10,515
-9,079
-6,631
EBIT
-8,402
-10,536
-9,127
-13,140
Net Income
-8,402
-10,494
-9,079
-6,222
Net Change In Cash
0
0
0
122
Cost of Revenue
3,523
Free Cash Flow
-7,858
-7,228
-7,317
-4,662
Cash
7,266
8,186
20,303
16,737
Basic Shares
14,511
12,718
12,472
10,958

Earnings Calls

Quarter EPS
2024-09-30
-$0.37
2024-06-30
-$0.50
2024-03-31
-$0.10
2023-12-31
-$0.12